About Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering "activation lethality," a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation. Rather than inhibiting cancer-driving pathways, the company selectively over-activates them to destroy tumor cells, advancing first-in-class targeted cancer medicines designed to be effective while combating the emergence of drug resistance. The company's platform integrates tumor genetics, novel functional genomics, and resistance biology to identify and develop differentiated oncology therapeutics.
Company details
Funding
Total raised
$67M
Last stage
Series A
Investors
Founders
Bill Sellers
Director of the cancer program at the Broad Institute of MIT and Harvard; led breakthrough research on activation lethality underlying Delphia's platform.
Mike Dillon
Former Chief Scientific Officer of IDEAYA Biosciences and former global head of discovery chemistry for oncology at Novartis Institutes for Biomedical Research (NIBR).
Kevin Marks
Two decades of experience as a cancer drug hunter; former head of oncology drug discovery at Novartis Institutes for Biomedical Research (NIBR) and head of biology at Agios Pharmaceuticals; co-founded Delphia in 2022 as entrepreneur-in-residence at GV.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.